Quest Diagnostics has announced the completed its acquisition of the laboratory businesses Med Fusion and Clear Point. Operating from a nearly 200,000 square foot facility in Lewisville, Texas, the two businesses form the basis for the company’s first national center of excellence in precision diagnostics for oncology. For patients with cancer, precision diagnostics, such as genomic sequencing of a tumor’s DNA, may help a physician select a therapy or clinical trial and monitor response.
In connection with the transaction, Quest is now a preferred provider to several organizations that are formerly owners of one or both of these businesses. These organizations include Baylor Scott & White Health (BSWH), The US Oncology Network (The Network), Texas Oncology, and Pathologists Bio-Medical Laboratories. Specifically, Quest will provide services on a preferred basis to 12 hospitals of BSWH in North Texas and 1,400 independent, community-based physicians nationally that are affiliated with The Network, including Texas Oncology. The Network is supported by McKesson Specialty Health, a division of McKesson Corporation.
Quest Diagnostics will collaborate with McKesson Specialty Health, The Network and Texas Oncology to enhance and nationally scale a model created by Med Fusion that standardizes next-generation gene sequencing panels to aid therapy selection and monitoring for cancer. This approach guides the physician, within an electronic health record, to a panel individualized according to guidelines to the patient’s cancer type and stage of disease.
